Symbols

IONS

Ionis Pharmaceuticals·NASDAQ

--(--)

IONS fundamentals

IONS Q4 2025 Earnings

Ionis Pharmaceuticals (IONS) released its earnings on Feb 25, 2026: revenue was 203.00M (YoY -10.57%), beat estimates; EPS was -1.41 (YoY -113.64%), missed estimates.

Revenue / YoY

203.00M

-10.57%

EPS / YoY

-1.41

-113.64%

Report date

Feb 25, 2026

IONS Earnings Call Summary for Q4,2025

Revenue Growth: 34% YoY to $944M, driven by commercial ($436M) and R&D ($508M).
Key Launches: TRYNGOLZA ($108M), DAWNZERA ($8M), and sHTG pipeline ($2B+ peak).
Pipeline Momentum: 5 late-stage partner readouts (Bepirovirsen, pelacarsen), 3 independent launches (sHTG, Zilganersen, Angelman).
Financial Discipline: 2026 guidance: $800-825M revenue, $500-550M non-GAAP loss.
Strategic Wins: FDA Breakthrough for olezarsen, 200+ field team expansion, $1.6B cash for growth.

Earnings

EPS

Revenue

Revenue & Expenses

IONS has released its 2025 Q4 earnings report, with revenue of 203.00M, reflecting a YoY change of -10.57%, and net profit of -229.00M, showing a YoY change of -120.19%. The Sankey diagram below clearly presents IONS's revenue sources and cost distribution.

Key Indicators

Ionis Pharmaceuticals (IONS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ionis Pharmaceuticals (IONS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ionis Pharmaceuticals (IONS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ionis Pharmaceuticals (IONS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown